Open AccessIron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis
Author(s) -
Francesca Punzo,
Chiara Tortora,
Maura Argenziano,
Maddalena Casale,
Silverio Perrotta,
Francesca Rossi
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0208102
Subject(s) - deferasirox , thalassemia , osteoporosis , osteoclast , eltrombopag , deferiprone , deferoxamine , medicine , chelation , bone remodeling , chelation therapy , myelodysplastic syndromes , pharmacology , chemistry , bone marrow , receptor , platelet , organic chemistry , immune thrombocytopenia
Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron chelator that prevents transfusion related iron overload complications. Recently Eltrombopag (ELT) iron chelating properties are emerging. ELT is an agonist at Thrombopoietin receptor, used in treatment of thrombocytopenia. We tested ELT and Deferasirox in iron overloaded osteoclasts from thalassemic patients and donors measuring intracellular iron, TRAP expression and osteoclast activity. We confirmed ELT iron chelation capacity also in bone tissue and a synergic effect when used with Deferasirox. Moreover, having demonstrated its effects on osteoclast activity, we suggest for the first time that ELT could ameliorate bone tissue’s health reducing bone mass loss.